KUALA LUMPUR, Aug 27 (Bernama) -- Varian, a Siemens Healthineers company, announced the launch of HyperSight imaging solution for its TrueBeam and Edge systems across the Asia Pacific (APAC) region (excluding China).
This upgrade gives clinicians unparalleled image quality, enhancing their ability to deliver precise and efficient radiation therapy treatments, as HyperSight optimises workflows across Varian’s entire suite of linear accelerators, enabling more tailored treatment for each patient.
“Guided by the evolving needs of radiation therapy based on current clinical trends, this innovation exemplifies our commitment to advancing clinical practice and providing high quality solutions for cancer patients everywhere.
“By combining advanced imaging with precise treatment delivery, we empower clinicians to deliver superior care,” said Varian APJ President, Hideaki Mori in a statement.
HyperSight acquires high-quality images and offers an extended field of view during a patient's daily radiation treatments, which is particularly beneficial for treating large cancers.
This facilitates accurate tumour volume targeting, reduces target volume margins, and preserves healthy tissue. It provides Hounsfield Unit (HU) accuracy needed for treatment planning directly on the acquired conebeam CT (CBCT) images, allowing clinicians to calculate changes in tumours and surrounding organs with greater precision, helping to adjust treatments more effectively.
This eliminates the need for separate CT scans, potentially avoiding extensions to a patient’s hospital stay. HyperSight is designed for all anatomical sites and has a 50 per cent faster gantry rotation compared to traditional CBCT scans, which can take up to 60 seconds.
For existing TrueBeam and Edge users, the upgrade seamlessly integrates with their systems, reducing motion-related artefacts due to patient movement and minimising discomfort from prolonged treatment times.
Varian is committed to supporting healthcare providers with an innovative portfolio of radiotherapy solutions, including HyperSight, and is working with regulators to review reimbursement models to support optimal patient care.
-- BERNAMA